Clinical Trials
6 trialsNCT06551142 2026-05-22
PanTumor-101
GlaxoSmithKline
Phase 1 Recruiting
NCT01042379 2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT06031233 2026-03-30
MINUTE
Isala
Phase 4 Recruiting
NCT06463665 2025-09-26
VIRO-25
Genelux Corporation
Phase 2 Recruiting
NCT03847649 2025-06-11
A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting